CRNO B
0.14 SEK
-0.09 (-40.30%)

Advancing pipeline with purpose

Interim Report Q3 2026

“These advances reflect the growing maturity of our pipeline, and across three differentiated programs, our focus is on measurable clinical, regulatory and preclinical milestones.”

Sten R. Sörensen

CEO

Learn more

Our equity story

Investment case

Stay up to date

Receive email alerts

To stay up to date with our development, subscribe to our news flow.

Subscribe
Investor questions

Contact

Investor questions

Tove Bergenholt, Head of IR & Communications

Email: [email protected]

Phone: +46(0)732-366 246